EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Anti-HER2×CCR4 bispecific antibody enhances antitumor immunity in advanced HER2-positive tumors by chemotaxis blockade and depletion of tumor-associated Tregs, without inducing systemic toxicity

Chaokun Wang, Jiachang Li, Yue Tong, Haotian Chang, Jingyi Xu, Hanchen Zhu, Yongmei Yin, Meng Meng, Rimo Xi

Journal for ImmunoTherapy of Cancer · 2025

DOI: 10.1136/jitc-2025-012829 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2025. Verfasst von Chaokun Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tia…. Hauptthemen laut MEDLINE: Antibodies, Bispecific, T-Lymphocytes, Regulatory, Erb-b2 Receptor Tyrosine Kinases, Receptors, CCR4. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

CCR4 + regulatory T cells (Tregs), which are widely present in peripheral circulation and tumor microenvironment (TME), promote tumor immune evasion by infiltrating human epidermal growth factor receptor 2-positive (HER2 + ) tumors in a chemokine-driven manner. However, therapies targeting CCR4 (eg, mogamulizumab) for systemic Treg depletion risk significant toxicity and have far been confined to hematological malignancies. Notably, tumor-chemotactic peripheral Tregs—key precursors to tumor-infiltrating Tregs (tumor-infiltrating lymphocyte (TIL)-Tregs)—remain overlooked.

Methods

We designed and expressed four candidate anti-HER2×CCR4 DVD-Ig bispecific antibodies with varying degrees of anti-CCR4 domain masking, while leaving anti-HER2 domains fully exposed, to preferentially deplete tumor-associated Tregs, including TIL-Tregs and tumor-chemotactic peripheral Tregs. Stability and antitumor activity were assessed in vitro. In human immune system-reconstituted NOG mice, we systematically: (1) conducted a comprehensive dose-response evaluation of the XL-11 to characterize pharmacological efficacy and potential systemic toxicity, (2) assessed the immune memory, (3) studied the synergy of XL-11 with programmed cell death protein-1/programmed death-ligand 1 (PD-1/L1) blocker, and (4) analyzed pharmacokinetic profile (PK).

Results

The lower affinity for CCR4 compared with HER2 enables anti-HER2×CCR4 DVD-Igs to priority target TIL-Tregs, and reduce binding to peripheral Tregs compared with mogamulizumab. Anti-HER2×CCR4 DVD-Igs inhibit Treg chemotaxis to TME, and killing Tregs and HER2 + tumor cells through antibody-dependent cellular cytotoxicity. Among the candidates, XL-11, which had the greatest exposure of the anti-CCR4 domain, was selected for in vivo evaluation due to its superior stability and potent antitumor activity. In vivo models of gastric cancer and breast cancer, XL-11, by reducing TIL-Tregs and increasing CD8 + /Tregs ratios, induces potent antitumor activity even in advanced stages, with no evidence of metastasis. Concurrently, XL-11 specifically depletes tumor-chemotactic peripheral Tregs, further enhancing antitumor immunity while avoiding reducing Tregs throughout the body even at a high dose (10 mg/kg). There was no increase in memory T cells. In addition, XL-11 enhances the antitumor activity of anti-PD-1 antibodies and shows superior PK properties.

Conclusions

XL-11 mediates potent antitumor immunity in advanced HER2 + tumors while avoiding reducing Tregs throughout the body. XL-11 also acts synergistically with anti-PD-1 therapy, and exhibits favorable stability and PK supporting clinical translation. This work advances Treg-targeted therapies in HER2 + tumors and overcomes the therapeutic limitations of mogamulizumab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificT-Lymphocytes, RegulatoryErb-b2 Receptor Tyrosine KinasesReceptors, CCR4AnimalsHumansMiceFemaleTumor MicroenvironmentChemotaxis

Stichwörter der Autor:innen

AntibodyBreast CancerGastric CancerImmunotherapyT regulatory cell - Treg

Substanzen

Antibodies, BispecificErb-b2 Receptor Tyrosine KinasesReceptors, CCR4ERBB2 protein, humanCCR4 protein, human

Autor:innen und Institutionen

  • State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin, China.
  • State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin, China xirimo@nankai.edu.cn.

Zitieren

APA

Wang, C., Li, J., Tong, Y., Chang, H., Xu, J., Zhu, H., Yin, Y., Meng, M., & Xi, R. (2025). Anti-HER2×CCR4 bispecific antibody enhances antitumor immunity in advanced HER2-positive tumors by chemotaxis blockade and depletion of tumor-associated Tregs, without inducing systemic toxicity. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-012829

Vancouver

Wang C, Li J, Tong Y, Chang H, Xu J, Zhu H, et al. Anti-HER2×CCR4 bispecific antibody enhances antitumor immunity in advanced HER2-positive tumors by chemotaxis blockade and depletion of tumor-associated Tregs, without inducing systemic toxicity. Journal for ImmunoTherapy of Cancer. 2025. doi:10.1136/jitc-2025-012829

BibTeX
@article{Wang2025,
  author = {Wang, Chaokun and Li, Jiachang and Tong, Yue and Chang, Haotian and Xu, Jingyi and Zhu, Hanchen and Yin, Yongmei and Meng, Meng and Xi, Rimo},
  title = {Anti-HER2×CCR4 bispecific antibody enhances antitumor immunity in advanced HER2-positive tumors by chemotaxis blockade and depletion of tumor-associated Tregs, without inducing systemic toxicity},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  doi = {10.1136/jitc-2025-012829}
}
Kostenlos starten →